Lataa...
免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望
With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors monotherapy as first-line and second-line treatment in advanced non-small cell lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing. Immune combination therapy expands the benefit population and...
Tallennettuna:
| Julkaisussa: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
中国肺癌杂志编辑部
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5973355/ https://ncbi.nlm.nih.gov/pubmed/28641702 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2017.06.10 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|